During the outbreak of COVID19 in Israel in Q2 2020, the Israeli MOH, through its procurement arm SAREL, faced a challenge to source the anti-viral drug - Lopinavir / Ritonavir due to a shortage at the leading manufacturer.

Bio-Lead took this challenge and within 3 days an alternative manufacturer from the US was targeted. Within 3 weeks, the drug was already in Israel.